Overview

A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia

Status:
Completed
Trial end date:
2017-12-12
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of ASP1517 in ESA-naive hemodialysis chronic kidney disease patients with anemia.
Phase:
Phase 3
Details
Lead Sponsor:
Astellas Pharma Inc
Collaborator:
FibroGen
Treatments:
Hematinics